Potential of Flavonoid-Inspired Phytomedicines against COVID-19

被引:110
|
作者
Ngwa, Wilfred [1 ,2 ]
Kumar, Rajiv [3 ,4 ]
Thompson, Daryl [5 ]
Lyerly, William [5 ]
Moore, Roscoe [5 ]
Reid, Terry-Elinor [6 ]
Lowe, Henry [7 ,8 ]
Toyang, Ngeh [7 ,8 ]
机构
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Northeastern Univ, Boston, MA 02115 USA
[4] Millipore Sigma, R&D Biomed Mat, Milwaukee, WI 53209 USA
[5] Global Res & Discovery Grp Sci, Winter Haven, FL 33884 USA
[6] Concordia Univ Wisconsin, Sch Pharm, Mequon, WI 53097 USA
[7] Vilotos Pharmaceut Inc, Baltimore, MD 21202 USA
[8] Flavocure Biotech Inc, Baltimore, MD 21202 USA
来源
MOLECULES | 2020年 / 25卷 / 11期
关键词
flavonoids and their derivatives; phytomedicine; COVID-19; SARS-COV-2; smart nanoparticles; CORONAVIRUS; RESPONSES;
D O I
10.3390/molecules25112707
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Flavonoids are widely used as phytomedicines. Here, we report on flavonoid phytomedicines with potential for development into prophylactics or therapeutics against coronavirus disease 2019 (COVID-19). These flavonoid-based phytomedicines include: caflanone, Equivir, hesperetin, myricetin, and Linebacker. Our in silico studies show that these flavonoid-based molecules can bind with high affinity to the spike protein, helicase, and protease sites on the ACE2 receptor used by the severe acute respiratory syndrome coronavirus 2 to infect cells and cause COVID-19. Meanwhile, in vitro studies show potential of caflanone to inhibit virus entry factors including, ABL-2, cathepsin L, cytokines (IL-1 beta, IL-6, IL-8, Mip-1 alpha, TNF-alpha), and PI4Kiii beta as well as AXL-2, which facilitates mother-to-fetus transmission of coronavirus. The potential for the use of smart drug delivery technologies like nanoparticle drones loaded with these phytomedicines to overcome bioavailability limitations and improve therapeutic efficacy are discussed.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Therapeutic Options and Potential Vaccine Studies Against COVID-19
    Bahadori, Fatemeh
    BEZMIALEM SCIENCE, 2020, 8
  • [32] An overview of some potential immunotherapeutic options against COVID-19
    Bayat, Maryam
    Asemani, Yahya
    Mohammadi, Mohammad Reza
    Sanaei, Mahsa
    Namvarpour, Mozhdeh
    Eftekhari, Reyhaneh
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 95
  • [33] Therapeutic Applications of Fucoidans and their Potential to Act Against COVID-19
    Yadav, Dhananjay
    Song, Minseok
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (46) : 3671 - 3676
  • [34] The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19
    Elnagdy, Sherif
    Alkhazindar, Maha
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2020, 3 (04) : 780 - 782
  • [35] Adverse effects of vaccinations and potential therapies against COVID-19
    Wasiak, Katarzyna
    Rieske, Piotr
    ALERGOLOGIA POLSKA-POLISH JOURNAL OF ALLERGOLOGY, 2022, 9 (01) : 14 - 32
  • [36] Type 1 interferons as a potential treatment against COVID-19
    Sallard, Erwan
    Lescure, Francois-Xavier
    Yazdanpanah, Yazdan
    Mentre, France
    Peiffer-Smadja, Nathan
    ANTIVIRAL RESEARCH, 2020, 178
  • [37] Time to realise the true potential of Ayurveda against COVID-19
    Golechha, Mahaveer
    BRAIN BEHAVIOR AND IMMUNITY, 2020, 87 : 130 - 131
  • [38] The potential of ODFs as carriers for drugs/vaccines against COVID-19
    Gupta, Maram Suresh
    Kumar, Tegginamath Pramod
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2021, 47 (02) : 179 - 188
  • [39] Pediatric vaccination against COVID-19 and despite COVID-19
    Martinon-Torres, Federico
    ANALES DE PEDIATRIA, 2022, 96 (01): : 4 - 7
  • [40] Correction: Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies
    Larissa Toigo
    Emilly Isabelli dos Santos Teodoro
    Ana Carolina Guidi
    Naiara Cássia Gancedo
    Marcus Vinícius Petruco
    Eduardo Borges Melo
    Fernanda Stumpf Tonin
    Fernando Fernandez-Llimos
    Danielly Chierrito
    João Carlos Palazzo de Mello
    Daniela Cristina de Medeiros Araújo
    Andréia Cristina Conegero Sanches
    DARU Journal of Pharmaceutical Sciences, 2024, 32 : 469 - 469